ArticleMolecular cancer therapeutics2019
Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis.
Registry-linked trialOpen access · bronzeAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04943211 (Determination of Molecular Status, as Well as the Efficacy and Safety of Fluorodeoxyglucose), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Determination of Molecular Status, as Well as the Efficacy and Safety of Fluorodeoxyglucose (18F-FDG) in PET-CT Imaging in Juvenile Patients With Histiocytosis
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Reliability of BRAF mutation detection using plasma sample: A systematic review and meta-analysisMedicine · 2021Pooled it
- Study of inborn errors of immunity associated lymphoid proliferations identifies association of presence of somatic variations with large cell morphology, copy number alterations in TNFAIP3 and heterozygous variants in EMSY.Virchows Archiv : an international journal of pathology · 2026Article
- Cardiovascular Involvement in Erdheim-Chester Disease Presenting as Pericardial Tamponade: A Case Report and Multimodality Imaging Review.Journal of clinical medicine · 2026Review
- Red-yellow Papules and Nodules All over the Body: A Quiz.Acta dermato-venereologica · 2026Article
- Article
- Tumour-agnostic kinase inhibitors.Nature reviews. Drug discovery · 2025Review
- If it is a solid tumor target, then it may be a hematologic cancer target: Bridging the great divide.Med (New York, N.Y.) · 2025Review
- Investigating the correlation between small molecular inhibitor utilization, peripheral blood monocytes, and treatment outcomes in Rosai Dorfman disease.Annals of hematology · 2024Article
- [Mutation pedigree and treatment selection of Erdheim-Chester disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
- ALK fusions in the pan-cancer setting: another tumor-agnostic target?NPJ precision oncology · 2023Review
- Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis.Blood advances · 2023Article
- Dramatic Response After Switching MEK Inhibitors in a Patient With Refractory Mixed Histiocytosis.Journal of hematology · 2022Article
- Limited sinonasal Rosai-Dorfman disease presenting as chronic sinusitis.Histopathology · 2022Article
- The potential of cell-free DNA to reveal the molecular profiles of Langerhans cell histiocytosis and Erdheim-Chester disease in adults.Leukemia · 2022Article
- Article
- Juvenile xanthogranuloma in Noonan syndrome.American journal of medical genetics. Part A · 2021Article
- Generalised eruptive histiocytosis preceded by systemic symptoms.BMJ case reports · 2021Article
- NRAS Mutations May Be Involved in the Pathogenesis of Cutaneous Rosai Dorfman Disease: A Pilot Study.Biology · 2021Article
- Disseminated non-Langerhans cell histiocytosis with an IRF2BP2-NTRK1 gene fusion identified by next-generation sequencing.JAAD case reports · 2020Article
- Erdheim-Chester disease: a rapidly evolving disease model.Leukemia · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Filip Janku *Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, Texas. fjanku@mdanderson.org diamone1@mskcc.org.
Eli L Diamond *Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York. fjanku@mdanderson.org diamone1@mskcc.org.
Aaron M GoodmanCenter for Personalized Cancer Therapy, Division of Blood and Marrow Transplantation, Division of Hematology/Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, California.
Vaijayanthi Kandadai RaghavanDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Tamara G BarnesDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Shumei KatoCenter for Personalized Cancer Therapy, Division of Blood and Marrow Transplantation, Division of Hematology/Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, California.
Omar Abdel-WahabDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Benjamin H DurhamDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Funda Meric-BernstamDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Razelle KurzrockCenter for Personalized Cancer Therapy, Division of Blood and Marrow Transplantation, Division of Hematology/Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, California.
Memorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MVIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9MOrigins of BRAF-mutant hematologic malignancies and their therapeutic resistanceR01CA201247 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ABDEL-WAHAB, OMAR, PARK, CHRISTOPHER Y · 2016 to 2020
$2.7MCellular Origins, Molecular Pathogenesis, and Novel Therapeutic Strategies for MAP Kinase-Driven Hematological MalignanciesK08CA218901 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DURHAM, BENJAMIN HEATH · 2018 to 2022
$1.0MNCI NIH HHS K08 CA218901NCI NIH HHS L30 CA231804NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA201247
Abstract
The
Indexed as
AdolescentAdultAgedCell-Free Nucleic AcidsEarly Detection of CancerErdheim-Chester DiseaseFemaleGenomicsHigh-Throughput Nucleotide SequencingHistiocytosis, SinusHumansLeukemia, MyeloidMaleMiddle AgedMitogen-Activated Protein KinasesMutationBRAF protein, humanCell-Free Nucleic AcidsMitogen-Activated Protein KinasesProto-Oncogene Proteins B-raf
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT04943211ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.